Brean Capital Analysts Give Vanda Pharmaceuticals Inc. (VNDA) a $24.00 Price Target
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) received a $24.00 price target from investment analysts at Brean Capital in a report issued on Monday. The firm presently has a a “buy” rating on the biopharmaceutical company’s stock. Brean Capital’s price target points to a potential upside of 36.13% from the company’s previous close.
Other equities analysts have also issued research reports about the company. Piper Jaffray Cos. set a $16.00 target price on Vanda Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 18th. Jefferies Group initiated coverage on Vanda Pharmaceuticals in a research note on Thursday, October 6th. They set a “buy” rating and a $23.00 target price on the stock. JMP Securities increased their target price on Vanda Pharmaceuticals from $18.00 to $22.00 and gave the stock a “market outperform” rating in a research note on Friday, August 26th. Finally, Zacks Investment Research lowered Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, July 6th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $20.00.
Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) traded down 2.10% during trading on Monday, reaching $17.26. The company’s stock had a trading volume of 543,930 shares. The company’s market cap is $747.08 million. The firm’s 50-day moving average is $15.70 and its 200 day moving average is $11.69. Vanda Pharmaceuticals has a 52-week low of $6.91 and a 52-week high of $18.00.
Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings data on Wednesday, July 27th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.12. The firm had revenue of $36.02 million for the quarter, compared to analyst estimates of $36.03 million. Vanda Pharmaceuticals had a negative return on equity of 22.51% and a negative net margin of 31.85%. The business’s revenue for the quarter was up 30.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.13) earnings per share. On average, equities research analysts predict that Vanda Pharmaceuticals will post ($0.61) EPS for the current fiscal year.
In related news, insider James E. Flynn sold 1,120,461 shares of the stock in a transaction that occurred on Friday, September 23rd. The stock was sold at an average price of $16.56, for a total transaction of $18,554,834.16. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider James E. Flynn sold 547,886 shares of the stock in a transaction that occurred on Monday, September 19th. The stock was sold at an average price of $15.66, for a total value of $8,579,894.76. The disclosure for this sale can be found here. Corporate insiders own 8.45% of the company’s stock.
Several large investors have recently modified their holdings of the stock. Teachers Advisors Inc. increased its stake in shares of Vanda Pharmaceuticals by 662.6% in the second quarter. Teachers Advisors Inc. now owns 454,871 shares of the biopharmaceutical company’s stock worth $5,090,000 after buying an additional 395,224 shares in the last quarter. Prudential Financial Inc. acquired a new stake in shares of Vanda Pharmaceuticals during the second quarter worth $3,962,000. Macquarie Group Ltd. increased its stake in shares of Vanda Pharmaceuticals by 24.6% in the second quarter. Macquarie Group Ltd. now owns 1,532,533 shares of the biopharmaceutical company’s stock worth $17,149,000 after buying an additional 302,591 shares in the last quarter. AJO LP acquired a new stake in shares of Vanda Pharmaceuticals during the second quarter worth $2,192,000. Finally, Palo Alto Investors LLC increased its stake in shares of Vanda Pharmaceuticals by 4.8% in the second quarter. Palo Alto Investors LLC now owns 4,225,608 shares of the biopharmaceutical company’s stock worth $47,285,000 after buying an additional 194,700 shares in the last quarter. 86.06% of the stock is currently owned by hedge funds and other institutional investors.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company’s product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051.
Receive News & Stock Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.